Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 104

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 104
---
 marketable securities(385,741)(542,608)Maturities of marketable securities735,161 365,891 Acquisition of Sage, net of cash acquired(293,093)— Purchases of property and equipment(911)(512)Net cash provided by (used in) investing activities55,416 (177,229)Cash flows from financing activitiesProceeds from issuance of common stock29,059 8,031 Employee taxes paid related to net share settlement of equity awards(4,198)(1,728)Payment of contingent consideration(24,257)— Net cash provided by financing activities604 6,303 Net change in cash, cash equivalents, and restricted cash83,490 (43,381)Cash and cash equivalents at beginning of year69,331 75,054 Cash, cash equivalents, and restricted cash at end of period$152,821 $31,673 Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets Cash and cash equivalents151,371 31,673 Restricted cash1,450 — Total cash, cash equivalents, and restricted cash shown in the statement of cash flows$152,821 $31,673 Supplemental cash flow informationCash paid for income taxes$15,780 $40,343 

See accompanying notes.

8

Supernus Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

1.    Business Organization

Supernus Pharmaceuticals, Inc. (the Company, see Consolidation in Note 2, Summary of Significant Accounting Policies) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.The Company has nine commercial products that it markets: Qelbree®, GOCOVRI®, Oxtellar XR®, Trokendi XR®, APOKYN®, XADAGO®, MYOBLOC® , ONAPGOTM  (formerly known as